1.中国中医科学院广安门医院肾病科,北京100053
2.中国中医科学院广安门医院南区肾病科,北京102600
3.北京中医药大学房山医院肾病科,北京102400
4.北京同仁堂股份有限公司科学研究所,北京100011
梁毓恬,女,28岁,硕士,住院医师。研究方向:中西医结合防治慢性肾脏病。
饶向荣,E-mail:raoyisheng@163.com
收稿:2025-07-18,
修回:2025-10-16,
录用:2025-10-22,
纸质出版:2025-09-25
移动端阅览
梁毓恬,郭传,廖熠蕾,等.乌鸡白凤丸治疗慢性肾脏病合并高尿酸血症患者的临床观察[J].北京中医药,2025,44(9):1111-1114.
LIANG Yutian,GUO Chuan,LIAO Yile,et al.Clinical efficacy of Wuji Baifeng Pills in the treatment of patients with hyperuricemia complicated by chronic kidney disease[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1111-1114.
梁毓恬,郭传,廖熠蕾,等.乌鸡白凤丸治疗慢性肾脏病合并高尿酸血症患者的临床观察[J].北京中医药,2025,44(9):1111-1114. DOI: 10.16025/j.1674-1307.2025.09.005.
LIANG Yutian,GUO Chuan,LIAO Yile,et al.Clinical efficacy of Wuji Baifeng Pills in the treatment of patients with hyperuricemia complicated by chronic kidney disease[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1111-1114. DOI: 10.16025/j.1674-1307.2025.09.005.
目的
2
观察乌鸡白凤丸干预2~4期慢性肾脏病(CKD)合并高尿酸血症(HUA),对患者血尿酸(SUA)水平、估算肾小球滤过率(eGFR)的影响。
方法
2
选取2022年7月至2024年12月中国中医科学院广安门医院及其南区、北京中医药大学房山医院肾病科门诊及住院的2~4期CKD合并HUA的脾肾亏虚、血虚血瘀证患者140例。采取计算机随机分组法分为2组,研究治疗过程中共脱落13例,剔除8例,最终纳入观察组59例,对照组60例。对照组给予一般生活方式干预及规范基础治疗,观察组在此基础上加用乌鸡白凤丸口服,1丸/次,2次/d,2组均连续干预12周。观察比较治疗前后2组患者的SUA、血肌酐(SCr)、eGFR及中医症状积分情况。
结果
2
治疗12周后,观察组SUA、SCr、eGFR水平均较治疗前改善(
P
<
0.05),且优于对照组(
P
<
0.05)。对照组治疗前后的SUA、SCr、eGFR水平比较,差异无统计学意义(
P
>
0.05)。治疗后,2组各项主
症的中医症状积分及总分均较治疗前下降,且观察组改善程度优于对照组(
P
<
0.05)。
结论
2
乌鸡白凤丸可有效降低2~4期CKD合并HUA脾肾亏虚、血虚血瘀证患者的SUA水平,改善其肾功能指标及相关临床症状,且安全性良好。
Objective
2
To observe the effects of
Wuji Baifeng Pills
on serum uric acid(SUA)levels and estimated glomerular filtration rate(eGFR)in patients with chronic kidney disease(CKD)stages 2~4 complicated by hyperuricemia (HUA).
Methods
2
A total of 140 patients with CKD stages 2~4 complicated by HUA treated.Patients were randomly assigned using computer-generated randomization.During the study,13 patients dropped out and 8 were excluded,leaving 59 patients in the treatment group and 60 in the control group.The control group received general lifestyle interventions and standard basic treatment,while the treatment group additionally received
Wuji Baifeng Pills
orally(1 pill per time, twice daily).Both groups were treated continuously for 12 weeks.SUA,serum creatinine(SCr),eGFR,and traditional Chinese medicine(TCM)syndrome scores were measured before and after treatment.
Results
2
During the study,13 cases dropped out and 8 were excluded.Ultimately,59 cases remained in the treatment group and 60 in the control group.After 12 weeks of treatment,the SUA level in the
Wuji Baifeng Pills
group was significantly lower than that in the control group(
P
<
0.05),and the within-group comparison before and after treatment also showed a statistically significant difference (
P
<
0.05).SCr and eGFR in the treatment group showed significant improvement compared to before treatment(
P
<
0.05). TCM syndrome scores and main symptom scores improved in both groups(
P
<
0.05). No patients required dialysis during the study. Three cases in the treatment group had mildly elevated transaminase levels.
Conclusion
2
Wuji Baifeng Pills
can effectively reduce SUA levels,improve related clinical symptoms and renal function indicators in patients with CKD stages 2~4 complicated by HUA (patterned as spleen-kidney deficiency with blood deficiency and blood stasis),with a good safety profile.
COCKWELL P , FISHER LA . The global burden of chronic kidney disease [J ] . Lancet , 2020 , 395 ( 10225 ): 662 - 664 .
LIU X , ZHAI T , MA R , et al . Effects of uric acid-lowering therapy on the progression of chronic kidney disease:a systematic review and meta-analysis [J ] . Ren Fail , 2018 , 40 ( 1 ): 289 - 297 .
NISHIZAWA H , MAEDA N , SHIMOMURA I . Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease [J ] . Hypertens Res , 2022 , 45 ( 4 ): 635 - 640 .
PALAZZUOLI A , RUOCCO G , PELLEGRINI M , et al . Prognostic significance of hyperuricemia in patients with acute heart failure [J ] . Am J Cardiol , 2016 , 117 ( 10 ): 1616 - 1621 .
ISEKI K , IKEMIYA Y , INOUE T , et al . Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort [J ] . Am J Kidney Dis , 2004 , 44 ( 4 ): 642 - 650 .
WHELTON A , MACDONALD PA , CHEFO S , et al . Preservation of renal function during gout treatment with febuxostat: a quantitative study [J ] . Postgrad Med , 2013 , 125 ( 1 ): 106 - 114 .
夏懿 , 王志敏 , 周家俊 . 乌鸡白凤丸治疗无症状高尿酸血症临床观察 [J ] . 贵阳中医学院学报 , 2017 , 39 ( 3 ): 62 - 66 .
GUAN Y , WU XX , DUAN JL , et al . Effects and mechanism of combination of rhein and danshensu in the treatment of chronic kidney disease [J ] . Am J Chin Med , 2015 , 43 ( 7 ): 1381 - 1400 .
CAO YW , XIONG JL , GUAN XP , et al . Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy [J ] . Phytomedicine , 2023 , 116 : 154901 .
Kidney Disease : Improving Global Outcomes(KDIGO)CKD Work Group . Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline [J ] . Ann Intern Med , 2013 , 158 ( 11 ): 825 - 830 .
Chinese Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases . Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases [J ] . Chin Med J (Engl) , 2017 , 130 ( 20 ): 2473 - 2488 .
郑筱萸 . 中药新药临床研究指导原则 [M ] . 北京 : 中国医药科技出版社 , 2002 : 69 .
袁钟瑜 , 谢惠迪 , 杜青 , 等 . 慢性肾脏病审因论治探析 [J ] . 北京中医药 , 2021 , 40 ( 11 ): 1225 - 1228 .
孙龙吉 , 李海松 , 冯伟栋 , 等 . 从“虚、瘀、浊”探讨高尿酸血症与勃起功能障碍共病的辨治思路 [J ] . 北京中医药 , 2025 , 44 ( 1 ): 19 - 22 .
杨怡坤 , 胡悦 , 连智华 , 等 . 胡荫奇从脾湿论治高尿酸血症经验 [J ] . 北京中医药 , 2020 , 39 ( 3 ): 244 - 246 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备 11010102006710号